The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound indicated by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), Ra and Rb together, and Rd and Re together form an oxo or the like R4a and R4b are hydrogen or the like n is 1 or the like R2 is an aryl or the like s and s are 0 or the like R9 and R9 are a halogen or the like R20a and R20b are hydrogen, an alkyl, or the like u is 1-4 and R13 is hydrogen or the like.